Abstract
Mild cognitive impairment (MCI) could be an auspicious candidate for an early marker of a beginning dementia. However, although MCI is accepted as a heterogeneous condition by now, performance testing or diagnosis is often based on a limited number of cognitive tests. Furthermore, there is still disagreement about the necessity to include subjective cognitive complaints as a diagnostic criterion. The current study intends to examine the character of MCI when diagnosis is based upon multiple cognitive domains and does not require the presence of subjective complaints. 130 subjects from the HelMA (Helmholtz Alliance for Mental Health in an Ageing Society) longitudinal study completed a comprehensive neuropsychological test-battery and were diagnosed as either normally-ageing controls or patients with MCI. The prevalence rate of MCI was as high as 46.2%, hereby exceeding most estimates of other studies. Patients with MCI performed worse than controls in each of the 29 administered tests with memory being the predominant impaired cognitive domain. Surprisingly, there was no single patient with a purely non-amnestic impairment, considerably contradicting hitherto existing studies. The rather different distribution of impairment and prevalence rate emphasizes the demand of testbatteries including all cognitive domains so that inferences about MCI are as all-encompassing as possible.
Keywords: Alzheimer’s disease, dementia, diagnosis, memory, mild cognitive impairment, neuropsychological assessment.
Current Alzheimer Research
Title:Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment
Volume: 10 Issue: 10
Author(s): E.I. Drexler, B. Voss, K. Amunts, F. Schneider and U. Habel
Affiliation:
Keywords: Alzheimer’s disease, dementia, diagnosis, memory, mild cognitive impairment, neuropsychological assessment.
Abstract: Mild cognitive impairment (MCI) could be an auspicious candidate for an early marker of a beginning dementia. However, although MCI is accepted as a heterogeneous condition by now, performance testing or diagnosis is often based on a limited number of cognitive tests. Furthermore, there is still disagreement about the necessity to include subjective cognitive complaints as a diagnostic criterion. The current study intends to examine the character of MCI when diagnosis is based upon multiple cognitive domains and does not require the presence of subjective complaints. 130 subjects from the HelMA (Helmholtz Alliance for Mental Health in an Ageing Society) longitudinal study completed a comprehensive neuropsychological test-battery and were diagnosed as either normally-ageing controls or patients with MCI. The prevalence rate of MCI was as high as 46.2%, hereby exceeding most estimates of other studies. Patients with MCI performed worse than controls in each of the 29 administered tests with memory being the predominant impaired cognitive domain. Surprisingly, there was no single patient with a purely non-amnestic impairment, considerably contradicting hitherto existing studies. The rather different distribution of impairment and prevalence rate emphasizes the demand of testbatteries including all cognitive domains so that inferences about MCI are as all-encompassing as possible.
Export Options
About this article
Cite this article as:
Drexler E.I., Voss B., Amunts K., Schneider F. and Habel U., Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment, Current Alzheimer Research 2013; 10 (10) . https://dx.doi.org/10.2174/15672050113109990014
DOI https://dx.doi.org/10.2174/15672050113109990014 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gastrointestinal Hemorrhage is Associated with Mortality after Acute Ischemic Stroke
Current Neurovascular Research Role of Cdk5 in Amyloid-beta Pathology of Alzheimer’s Disease
Current Alzheimer Research Medical Expert Systems
Current Bioinformatics Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Current Drug Targets Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Current Alzheimer Research Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry Radix Angelica Sinensis that Contains the Component Z-Ligustilide Promotes Adult Neurogenesis to Mediate Recovery from Cognitive Impairment
Current Neurovascular Research Cortical and Subcortical Changes in Alzheimer’s Disease: A Longitudinal and Quantitative MRI Study
Current Alzheimer Research